Detachable coupling for catheter

Information

  • Patent Grant
  • 10124087
  • Patent Number
    10,124,087
  • Date Filed
    Tuesday, June 19, 2012
    12 years ago
  • Date Issued
    Tuesday, November 13, 2018
    6 years ago
Abstract
A microcatheter comprising an elongate flexible tubular body, a tip body and a coupling is disclosed. The elongate flexible tubular body has a proximal end, a distal end and at least one lumen extending axially therethrough. The tip body has a proximal end and a distal end and a lumen extending axially therethrough. The coupling covers a portion of both the tubular body and tip body and is made from a first material and a second material, where the first material is different from the second material. The first material is compatible with an outermost layer of the tubular body and an outermost layer of the tip body, and the second material is configured to form a detachable bond with at least one of the tubular body and the tip body.
Description
BACKGROUND

1. Technical Field


The present disclosure generally relates to microcatheters, and, in particular, a microcatheter with a detachable, biocompatible tip.


2. Description of Related Art


Microcatheters are generally inserted into the body through a blood vessel such as the femoral artery and have a variety of uses in the vasculature. Microcatheters may be used to assist in the treatment of various neurovascular conditions such as arteriovenous malformations (AVMs) and aneurysms.


Aneurysms and AVMs may be treated intravascularly with compositions delivered through microcatheters which solidify in vivo so as to permanently occlude blood flow to cerebral aneurysms and cerebral arteriovenous malformations. Suitable intravascular compositions include, by way of example only, cyanoacrylates which polymerize in vivo to form a solid mass as well as solutions of a biocompatible, water insoluble polymer dissolved in a non-aqueous solvent such as dimethyl sulfoxide (“DMSO”) whereupon introduction into the vasculature, the DMSO dissipates and the polymer precipitates in the aqueous based blood composition. Such intravascular compositions further comprise a contrast agent to assist in visualization of the formed mass.


Embolic compositions are delivered to the embolization site from a microcatheter. As the embolic composition solidifies in vivo there may be “flow back” or “reflux” of the composition such that the distal tip of the microcatheter becomes entrapped there within. When this occurs, the clinician either must attempt to withdraw the microcatheter by force, often resulting in microcatheter breakage, or must cut the catheter, leaving the distal tip within the patient's vasculature.


SUMMARY

Accordingly, the present disclosure is directed to providing a microcatheter which can be safely removed from the patient in the event the distal tip becomes trapped in the vasculature for any reason, while minimizing the potential risks caused by such complications.


The present disclosure is directed to a microcatheter comprising an elongate flexible tubular body, a tip body and a coupling. The elongate flexible tubular body has a proximal end, a distal end and at least one lumen extending axially therethrough. The tip body has a proximal end and a distal end and a lumen extending axially therethrough. The coupling covers a portion of both the tubular body and tip body and is made from a first material and a second material, where the first material is different from the second material. The first material is compatible with an outermost layer of the tubular body and an outermost layer of the tip body. The second material is configured to form a detachable bond with at least one of the tubular body and the tip body.


In disclosed embodiments, the first material is disposed radially outwardly of the second material, e.g., along an entire length of the second material. Here, it is disclosed that the first material is disposed radially outwardly of the second material along an entire length of the first material.


In disclosed embodiments, the second material is in direct contact with the tubular body.


In disclosed embodiments, the first material is selected from the group consisting of Polyurethane, Polyethylene, Polytetrafluoroethylene (PTFE), Expanded Polytetrafluoroethylene (EPTFE), Polyether block amide, Polyvinyl chloride (PVC), and Polypropylene. In disclosed embodiments, the second material is selected from the group consisting of Low Density Polyethylene (LDPE), Linear Low Density Polyethylene (LLDPE) and High-density polyethylene (HDPE). Here, it is disclosed that the tubular body is made from the first material.


In disclosed embodiments, a third material is disposed between the first material and the second material.


In disclosed embodiments, the first material is compatible with a hydrophilic coating.


In disclosed embodiments, the coupling is a single unit.


In disclosed embodiments, a hydrophilic coating is included and is in contact with the tubular body, the tip body and the first material.


In disclosed embodiments, a hydrophilic coating is in contact with the tubular body, the tip body and the first material.


The present disclosure is also directed to a microcatheter comprising a tubular body, a tip body and a coupling. The tubular body has a proximal portion, a distal portion, and a lumen extending from the proximal portion to the distal portion for introducing a fluid agent. The tubular body is made from a first material. The tip body is coupled to the distal portion of the tubular body and defines a central lumen communicating with the lumen of the tubular. The coupling is engaged with a portion of the tubular body via a first bond, and engaged with a portion of the tip body via a second bond. The coupling is made from at least two different materials including the first material and a second material. The first bond and the second bond have different bond strengths.


In disclosed embodiments, the first bond is stronger than the second bond.


In disclosed embodiments, the first material is selected from the group consisting of Polyurethane, Polyethylene, Polytetrafluoroethylene (PTFE), Expanded Polytetrafluoroethylene (EPTFE), Polyether block amide, Polyvinyl chloride (PVC), and Polypropylene. In disclosed embodiments, the second material is selected from the group consisting of Low Density Polyethylene (LDPE), Linear Low Density Polyethylene (LLDPE) and High-density polyethylene (HDPE).


The present disclosure is also directed to a method of manufacturing a microcatheter. The method comprises providing an elongate flexible tubular body having a proximal end, a distal end and at least one lumen extending axially therethrough. The method also comprises providing a tip body having a proximal end and a distal end and a lumen extending axially therethrough. The method further comprises providing a coupling made of a first material and a second material, where the first material is different from the second material, and where the first material is compatible with an outermost layer of the tubular body and an outermost layer of the tip body. The method also comprises heating a portion of the tubular body and a portion of the coupling to form a first bond therebetween, heating a portion of the tip body and a portion of the coupling to form a second bond therebetween. The first and second bonds have different bond strengths.





BRIEF DESCRIPTION OF THE DRAWINGS

Embodiments of the present disclosure will be readily appreciated by reference to the drawings wherein:



FIG. 1 is a side plan view of a catheter in accordance with the present disclosure;



FIG. 2 is a perspective view of a portion of the catheter of FIG. 1 illustrating the tubular body, tip body and coupling;



FIGS. 3 and 4 illustrate the catheter of FIGS. 1 and 2 in use within a tortuous region of the vasculature of a patient in accordance with the principles of the present disclosure;



FIG. 5 is a longitudinal cross-sectional view of a first embodiment of a coupling in accordance with the present disclosure;



FIG. 5A is a transverse cross-sectional view of the coupling of FIG. 5 taken along line 5A-5A;



FIG. 5B is a transverse cross-sectional view of the coupling of FIG. 5 taken along line 5B-5B;



FIG. 6 is a longitudinal cross-sectional view of a second embodiment of a coupling in accordance with the present disclosure;



FIG. 6A is a transverse cross-sectional view of the coupling of FIG. 6 taken along line 6A-6A;



FIG. 6B is a transverse cross-sectional view of the coupling of FIG. 6 taken along line 6B-6B;



FIG. 7 is a longitudinal cross-sectional view of a third embodiment of a coupling in accordance with the present disclosure;



FIG. 7A is a transverse cross-sectional view of the coupling of FIG. 7 taken along line 7A-7A; and



FIG. 7B is a transverse cross-sectional view of the coupling of FIG. 7 taken along line 7B-7B.





DESCRIPTION

In the following description, the terms “proximal” and “distal” as used herein refer to the relative position of the microcatheter in a lumen. The “proximal” or “trailing” end of the microcatheter is the microcatheter segment extending outside the body closest to the clinician. The “distal” or “leading” end of the microcatheter is the microcatheter segment placed farthest into a body lumen from the entrance site.


With reference to FIG. 1, a microcatheter 10 can be useful for delivering embolic agents to vascular sites of patients. Though microcatheters can be used in any vessel in the body, they are particularly useful for embolizing aneurysms or AVMs in the neurovasculature. Microcatheter 10 includes a tubular body segment 16 defining longitudinal axis “a” and having a distal or leading end 12 and a proximal or trailing end 14. Microcatheter 10 further includes a tip body 30 which is coaxial with the tubular body 16 and detachably connected or engaged to tubular body 16 through a coupling 100. The term “detachably engaged” or “detachably connected” is intended to include an interpretation where tip body 30 may be released from tubular body 16 upon application of a retraction force that may be a predetermined value depending on the intended use of the microcatheter 10. For example, the predetermined force may be a tensile force applied along the longitudinal axis “a” to at least one of tubular body 16, tip body 30 or coupling 100. In other embodiments, the predetermined force may be a shearing or radial force applied to the components. The term “retraction force” is generally a tensile force applied along the longitudinal axis of the microcatheter 10, for example, parallel to a central lumen 22, in the proximal direction, that is in the direction that would withdraw the microcatheter from the patient. The retraction force used to detach the tubular body 16 from the tip body 30 can, for example, be no more than about 160 gram-force and more particularly can range from about 10 gram-force to about 160 gram-force. In certain embodiments, the retraction force is about 20 gram-force to about 40 gram-force. In other embodiments, the retraction force is about 30 gram-force to about 50 gram-force. Other ranges than those described above can also be used. Various embodiments of coupling 100 will be discussed in greater detail hereinbelow.


Referring to FIGS. 1 and 2, the tubular body 16 and the tip body 30 can be of the same or different outer and inner diameters. The proximal end 14 of microcatheter 10 may include a manifold 18. Manifold 18 may include at least one access port 20 in fluid communication with a distal access port 24 by way of an elongate central lumen 22. Central lumen 22 permits the microcatheter 10 to track over a guidewire (not shown). After removal of the guidewire, the central lumen 22 may be used to deliver an embolic agent to the desired vascular site. Although not specifically illustrated, the microcatheter 10 may contain a plurality of lumens. For example, one lumen may be dedicated for use by a guidewire, while another lumen may be dedicated to delivery of the embolic agent. The microcatheter 10 may include a marker 32, for example a radiopaque marker, located adjacent the distal end 12 of the tubular body 16. The marker 32 can be a ring or band made from a metal or metal alloy, such as platinum, platinum/iridium, gold, nitinol and the like. In disclosed embodiments, coupling 100 may be filled with a radiopaque material, such as barium sulfate.


To further assist in the delivery of the embolic agent to the desired vascular site, the tip body 30 may optionally contain a plurality of lateral apertures or holes 38. The shape of the apertures 38 may be selected from round, elliptical, or other shapes.


The total length of the microcatheter 10 can generally be in the range of from about 150 cm to about 175 cm, although other ranges are also possible. The tubular body 16 can be selected to have an outside diameter within the range of about 0.5 mm to about 1.5 mm, although other diameters are also possible. In some embodiments, the diameter of the central lumen 22 can be between about 0.002 inches and about 0.005 inches larger than the outside diameter of the guidewire, if one is used. This diameter can be modified appropriately at the proximal and distal ends. Other dimensions than those described herein can be readily utilized by those of ordinary skill in the art in view of the disclosure herein to suit particular intended uses of the microcatheter 10.


The tubular body 16 can be constructed of a variety of materials and in a variety of ways. It is envisioned that the tubular body 16 is made from a material selected from the group consisting of Polyurethane, Polyethylene, Polytetrafluoroethylene (PTFE), Expanded Polytetrafluoroethylene (EPTFE), Polyether block amide (including those branded Pebax®), Polyvinyl chloride (PVC), and Polypropylene. In disclosed embodiments, the tubular body 16 may be constructed of a material that is compatible with dimethylsulfoxide. The tubular body 16 may also contain zones with varying flexibility which can also be controlled by the methods of construction and materials employed. The tubular body 16 may also be constructed by layering various polymers, such polyimide, polytetrafluoroethylene, polyether block amides, polyamide and the like. The tubular body 16 may additionally include a braid of varying pitches. The tip body 30 is made from a biocompatible material. What is meant by “biocompatible” is that the material, in the amounts employed, are substantially non-toxic and substantially non-immunogenic when used in the vasculature of a patient. For example, it is envisioned that the tip body 30 is made from a material selected from the group consisting of Polyurethane, Polyethylene, Polytetrafluoroethylene (PTFE), Expanded Polytetrafluoroethylene (EPTFE), Polyether block amide, Polyvinyl chloride (PVC), and Polypropylene. It is further envisioned that the tip body 30 is made from the same material as the tubular body 16.


In certain embodiments, the tip body 30 can also be “biodegradable.” A wide variety of biodegradable/bioerodable and non-biodegradable materials are known which are useful for constructing microcatheter tips. The tip body 30 can be formed of a material which is biodegradable or bioabsorbable in situ. Biodegradable or bioabsorbable materials, or some combination thereof, can be used which allow for the biodegradation/bioabsorption in predetermined conditions.


A variety of biocompatible-biodegradable materials are commercially available and suitable for use in these embodiments. Examples of these materials include DLPLA-poly(dl-lactide), LPLA-poly(1-lactide), PGA-polyglycolide, PDO-poly(dioxanone), PGA-TMC-poly(glycolide-co-trimethylene carbonate), PGA-LPLA-poly(1-lactide-co-glycolide), PGA-DLPLA-poly(dl-lactide-co-glycolide), LPLA-DLPLA-poly(1-lactide-co-dl-lactide), and PDO-PGA-TMC-poly(glycolide-co-trimethylene carbonate-co-dioxanone).


It is further envisioned that a lubricious coating may be disposed over components of microcatheter 10, including tubular body 16, coupling 100 and tip body 30. Suitable lubricious coatings include hydrophilic materials such as polyvinylpyrrolidone (PVP), polyethylene oxide, polyethylene glycol, cellulosic polymers, and hydrophilic maleic anhydride, or hydrophobic materials such as silicone, PTFE, or FEP. These coatings are typically applied by dip coating or spray methods, and heat or Ultraviolet (UV) curing may be used. For example, cure temperatures up to about 70 degrees C. are used for silicone coatings, and several hundred degrees C. may be required for PTFE coatings. In addition to the lubricious coating, bioactive coatings may be applied over all or part of the microcatheter. Such coatings also may incorporate materials such as heparin, hirudin and its analogs, or other chugs. These coatings typically are applied by dip coating. Bioactive coatings are desirable to prevent blood clotting or for delivery of drugs to a specific site.


Various embodiments of coupling 100 are shown in the accompanying figures. With reference to FIGS. 5-5B, a first embodiment of a coupling 100a is shown. Coupling 100a is made from a first material 110a, and a second material 120a. Additionally, an optional third material 130a is shown between first material 110a and second material 120a and may be used to form a bond therebetween. In the embodiment illustrated in FIGS. 5-5B, first material 110a, and second material 120a extend the entire length “L” of coupling 100a. Additionally, first material 110a is disposed radially outwardly of second material 120a along the entire length “L” of coupling 100a.


It is envisioned that first material 110a of coupling 100a includes a material that is compatible with an outermost layer of the tubular body 16 and the outermost layer of the tip body 30, such as a hydrophilic coating, as discussed above. As can be appreciated, materials that are compatible with a hydrophilic coating include materials that the hydrophilic coating can adhere to by dipping, sponge coating, spraying, or any other conventional coating techniques well known in the art. For example, it is envisioned that first material 110a includes Polyurethane, Polyethylene, Polytetrafluoroethylene (PTFE), Expanded Polytetrafluoroethylene (EPTFE), Polyether block amide, Polyvinyl chloride (PVC), or Polypropylene. It is further envisioned that first material 100a is the same material that tubular body 16 is made from.


With regard to second material 120a of coupling 100a, it is envisioned that second material 120a includes a material that is capable of forming a bond with tubular body 16 and a detachable bond with tip body 30. Accordingly, it is envisioned that second material 120a of coupling 100a includes Low Density Polyethylene (LDPE), Linear Low Density Polyethylene (LLDPE) or High-density polyethylene (HDPE), for example. In embodiments where tubular body 16 is made from the same material as tip body 30, for example, it is envisioned that forming the bonds with different bond strengths is accomplished by heating the bonds at different temperatures. For example, to provide a relatively strong bond between tubular body 16 and coupling 100a, the bond could be created by heating the area at a temperature of between about 350° F. and about 354° F., for example, and for a duration of about 7 seconds, for example; to provide a relatively weak bond between tip body 30 and coupling 100a, the bond could be created by heat the area at a temperature of between about 246° F. and about 250° F., for example, and for a duration of about 6 seconds, for example.


Thus, in disclosed embodiments, the coupling 100a is attached to tubular body 16 via a strong bond relative to the strength of the bond connecting coupling 100a and tip body 30. In these embodiments, a suitable retraction force applied by a clinician would result in coupling 100a detaching from tip body 30, and coupling 100a remaining connected to tubular body 16. As can be appreciated, the strong bond and weak bond can be switched depending on the desired results. In a disclosed embodiment, first material 110a is a Polyether block amide, second material 120a is a Low Density Polyethylene, and at least a portion of tubular body 16 is a Polyether block amide.


Additionally, third material 130a, which may be used to form a bond between first material 110a and second material 120a, can be made from Plexar, TYMAX™, or Dupont™ Bynel®. In particular, it is envisioned that when first material 110a is made from Pebax, and when second material 120a is made from LDPE, third material 130a is made from Plexar.


With reference to FIGS. 6-6C, a second embodiment of coupling 100 is shown and is indicated as coupling 100b. Coupling 100b is made from a first material 110b and a second material 120b. As shown, first material 110b is disposed radially outwardly of second material 120b along the entire length of second material 120b. Additionally, there is a line of distinction 140b between first material 110b and second material 120b, such that second material 120b only extends a portion of the length “L” of coupling 100b. While the line of distinction 140b is shown near the longitudinal midpoint of coupling 100b, it is envisioned that the line of distinction 140b is located farther proximally or distally than the location shown. Additionally, it is envisioned that first material 110b is selected from the same group of materials as first material 110a, and second material 120b is selected from the same group of materials as second material 120a. Further, while not explicitly illustrated, a third material may be disposed between first material 110b and second material 120b, and may include the same material(s) as third material 130a.


With reference to FIGS. 7-7C, a third embodiment of coupling 100 is shown and is indicated as coupling 100c. Coupling 100c is made from a first material 110c and a second material 120c. As shown, the entirety of first material 110c is disposed proximally of the entirety second material 120c. Additionally, there is a line of distinction 140c between first material 110c and second material 120c. While the line of distinction 140c is shown near the longitudinal midpoint of coupling 100c and adjacent the junction of tubular body 16 and tip body 30, it is envisioned that the line of distinction 140c is located farther proximally or distally than the location shown. Additionally, it is envisioned that first material 110c is selected from the same group of materials as first material 110a, and second material 120c is selected from the same group of materials as second material 120a. Further, while not explicitly illustrated, a third material may be disposed between first material 110c and second material 120c, and may be selected from the same group of materials as third material 130a.


Referring back to FIG. 3, the use of the microcatheter 10 within the human body is illustrated. Specifically, the microcatheter 10 is inserted into the patient in a convenient location, such as the groin. The microcatheter 10 is advanced through the vasculature until the tip body 30 reaches a treatment site 40, such as for example an AVM or aneurysm. The position of the microcatheter 10 can be monitored by visualizing the radiopaque marker 32. Once the microcatheter 10 is in its appropriate position in the vasculature, embolic agent 42 can be delivered to the treatment site 40. The embolic agent 42 can be a liquid embolic agent and can comprise of a number of materials. Suitable embolic agents 42 include those containing biocompatible polymers and prepolymers which polymerize in situ. The liquid embolic agent can also comprise a biocompatible solvent and a contrast agent. In one embodiment, the contrast agent is water-insoluble. One such example is Onyx™, a non-adhesive liquid embolic agent comprised of EVOH (ethylene vinyl alcohol) copolymer dissolved in DMSO (dimethyl sulfoxide) and suspended micronized tantalum powder to provide contrast for visualization under fluoroscopy, commercially available from Tyco Healthcare Group LP dba Covidien, Irvine, Calif. Further description of suitable embolic agents are described in U.S. Pat. Nos. 5,667,767; 5,695,480; 6,051,607; 6,342,202; 6,531,111; and 6,562,317 all of which are incorporated by reference herein and made a part of this specification.


Referring to FIGS. 3 and 4, after delivery of the embolic agent 42, the tip body 30 can be entrapped within the agent 42. To remove the microcatheter 10 from the patient, the attending clinician can apply a retraction force to the tubular body 16. Generally, when the retraction force is applied, the coupling 100 can either 1) remain attached to the tip body 30; 2) remain attached to the tubular body 16; or 3) break into two components thereby remaining partially attached to both the tubular body 16 and the tip body 30.


The condition of the coupling 100 after application of the force can be influenced by the materials of construction of the components and the approach utilized in engaging the coupling 100 to the tip body 30 and the tubular body 16. The engagement of the tip body 30 to the coupling 100 and the engagement of the tubular body 16 to the coupling 100 can be accomplished in variety of ways. For example, the coupling 100 can overlap with a distal end 34 of the tubular body 16 and/or can overlap with a proximal end 36 of the tip body 30 (see FIG. 2). The amount of overlap can be a factor in determining the retraction force used for detaching the tip body 30. In some embodiments, one or both attachments of the coupling 100 to the tip body 30 or the tubular body 16 can be a butt joint (end to end). In some embodiments, the distal end 34 and proximal end 36 can form a butt joint.


The present disclosure also relates to a method of manufacturing microcatheter 10 and/or coupling 100, as disclosed herein. Accordingly, it is envisioned that coupling 100 for use with microcatheter 10 is made via coextrusion or from a mold (e.g., molding or overmolding). Additionally, as discussed above, it is envisioned that coupling 100 is bonded to catheter 10 via hot bonding. It particular, coupling 100 may be bonded to tubular body 16 by heating coupling 100/tip body 16 to a temperature of between about 350° F. and about 354° F. for about 7 seconds, and coupling 100 may be bonded to tip body 30 by heating coupling 100/tip body 30 to a temperature of between about 246° F. and about 250° F. for about 6 seconds. When the heat source is applied, the coupling 100 can attach to the tubular body 16 and the tip body 30 by either a mechanical bond (force of the heat shrinking around the smaller tubular body 16 and tip body 30) or a fused bond (where the materials of the coupling 100, the tubular body 16, and/or the tip body 30 are melted together).


In an alternative method of construction, the coupling 100 can be attached to the tip body 30 and/or tubular body 16 by use of adhesives, hot air, laser, hot die, plasma treating or solvent bonding.


It is further envisioned that there can be varying amounts of overlap of the coupling 100 with the tubular body 16 and/or the tip body 30. The amount of overlap can be one factor in the retraction force required to separate the tip body 30 from the tubular body 16 and/or coupling 100. For example, it is envisioned that the larger the overlap of the coupling 100 on either the tubular body 16 and/or the tip body 30, the greater the retraction force required to detach the two components. In some embodiments, this overlap can be from about 0.5 mm to about 5 mm. In some embodiments, the overlap can be between about 2 mm to about 4 mm. Other overlap ranges are also possible.


The above description and the drawings are provided for the purpose of describing embodiments of the present disclosure and are not intended to limit the scope of the disclosure in any way. For example, while each embodiment of coupling 100a-100c illustrates tubular body 16 in contact with tip body 30, it is envisioned that there is a space therebetween. It will be apparent to those skilled in the art that various modifications and variations can be made without departing from the spirit or scope of the disclosure. Thus, it is intended that the present disclosure cover the modifications and variations of this disclosure provided they come within the scope of the appended claims and their equivalents.

Claims
  • 1. A microcatheter comprising: an elongate flexible tubular body having a proximal end, a distal end and at least one lumen extending axially therethrough;a tip body having a proximal end and a distal end and a lumen extending axially therethrough;a coupling covering a portion of both the tubular body and tip body, the coupling comprising a first layer and a second layer made from different materials, the first layer being made from a first material and the second layer being made from a second material, wherein the first material is different from the second material; anda hydrophilic coating applied to at least the coupling and the tip body,wherein the first material of the coupling is compatible with the hydrophilic coating, andwherein the second material of the coupling is configured to form a detachable bond with at least one of the tubular body and the tip body.
  • 2. The microcatheter of claim 1 wherein the first layer is disposed radially outwardly of the second layer.
  • 3. The microcatheter of claim 2 wherein the first layer is disposed radially outwardly of the second layer along an entire length of the second layer.
  • 4. The microcatheter of claim 3 wherein the first layer is disposed radially outwardly of the second layer along an entire length of the coupling.
  • 5. The microcatheter of claim 1 wherein the second layer is in direct contact with the tubular body.
  • 6. The microcatheter of claim 5 wherein the second layer of the coupling is in direct contact with the tubular body and with the tip body.
  • 7. The microcatheter of claim 1 wherein the first material is selected from the group consisting of Polyurethane, Polyethylene, Polytetrafluoroethylene (PTFE), Expanded Polytetrafluoroethylene (EPTFE), Polyether block amide, Polyvinyl chloride (PVC), and Polypropylene.
  • 8. The microcatheter of claim 7 wherein the tubular body is made from the first material.
  • 9. The microcatheter of claim 1 wherein the second material is selected from the group consisting of Low Density Polyethylene (LDPE), Linear Low Density Polyethylene (LLDPE) and High-density polyethylene (HDPE).
  • 10. The microcatheter of claim 1 wherein the tubular body is made from the first material.
  • 11. The microcatheter of claim 1 wherein the first material is Polyether block amide and wherein the second material is Low Density Polyethylene, and wherein at least a portion of the tubular body is made from Polyether block amide.
  • 12. The microcatheter of claim 1 further comprising a third layer made from a third material, the third layer being disposed between the first layer and the second layer.
  • 13. The microcatheter of claim 1 wherein the coupling is a single unit.
  • 14. The microcatheter of claim 1 wherein the hydrophilic coating is in contact with the tubular body, the tip body and the first layer of the coupling.
  • 15. The microcatheter of claim 1 wherein the first layer does not contact the tip body.
  • 16. The microcatheter of claim 1 wherein the first layer extends along an entire length of the coupling.
  • 17. The microcatheter of claim 1 wherein the first and second layers each only extends along a portion of a length of the coupling.
  • 18. The microcatheter of claim 1 wherein the coupling is configured such that an entirety of the first material is disposed proximally of an entirety of the second material.
  • 19. A microcatheter comprising: a tubular body having a proximal portion, a distal portion, and a lumen extending from the proximal portion to the distal portion for introducing a fluid agent, the tubular body being made from a first material;a tip body coupled to the distal portion of the tubular body and defining a central lumen communicating with the lumen of the tubular body;a coupling engaged with a portion of the tubular body via a first bond, and engaged with a portion of the tip body via a second bond, the coupling comprising a first layer and a second layer being made from different materials, the first layer being made from the first material and the second layer being made from a second material, wherein the first bond and the second bond have different bond strengths; anda hydrophilic coating applied to at least the coupling and the tip body, the first material of the coupling being compatible with the hydrophilic coating.
  • 20. The microcatheter of claim 19 wherein the first bond is stronger than the second bond.
  • 21. The microcatheter of claim 19 wherein the first material is selected from the group consisting of Polyurethane, Polyethylene, Polytetrafluoroethylene (PTFE), Expanded Polytetrafluoroethylene (EPTFE), Polyether block amide, Polyvinyl chloride (PVC), and Polypropylene.
  • 22. The microcatheter of claim 21 wherein the second material is selected from the group consisting of Low Density Polyethylene (LDPE), Linear Low Density Polyethylene (LLDPE) and High-density polyethylene (HDPE).
  • 23. The microcatheter of claim 19 wherein the first and second layers define a line of distinction between the first and second materials.
  • 24. The microcatheter of claim 19 wherein the first layer extends along an entire length of the coupling.
  • 25. The microcatheter of claim 19 wherein the coupling is configured such that an entirety of the first material is disposed proximally of an entirety of the second material.
  • 26. A method of manufacturing a microcatheter, the method comprising: heating a portion of an elongate flexible tubular body and a portion of a coupling to form a first bond therebetween, the tubular body having a proximal end, a distal end, and at least one lumen extending axially therethrough, and the coupling comprising a first layer and a second layer made from different materials, the first layer being made from a first material and the second layer being made from a second material, wherein the first material is different from the second material; andheating a portion of a tip body and a portion of the coupling to form a second bond therebetween, wherein the first bond and the second bond have different strengths, the tip body having a proximal end and a distal end and a lumen extending axially therethrough: andapplying a hydrophilic coating to the coupling, to the tubular body and to the tip body, the first material of the coupling being compatible with the hydrophilic coating.
  • 27. The microcatheter of claim 1 wherein the first and second layers define a line of distinction between the first and second materials.
  • 28. The method of claim 26 wherein the first and second layers define a line of distinction between the first and second materials.
US Referenced Citations (209)
Number Name Date Kind
2326159 Mendel Aug 1943 A
3058473 Whitehead Oct 1962 A
3656485 Robertson Apr 1972 A
3656486 Robertson Apr 1972 A
3674014 Tillander Jul 1972 A
3977409 Brendling Aug 1976 A
4346712 Handa et al. Aug 1982 A
4364392 Strother et al. Dec 1982 A
4385631 Uthmann May 1983 A
4395806 Wonder et al. Aug 1983 A
4402319 Handa et al. Sep 1983 A
4545367 Tucci Oct 1985 A
4631188 Stoy et al. Dec 1986 A
4655762 Rogers Apr 1987 A
4663358 Hyon et al. May 1987 A
4698056 Ciannella Oct 1987 A
4739768 Engelson Apr 1988 A
4808155 Mahurkar Feb 1989 A
4819637 Dormandy, Jr. Apr 1989 A
4863442 DeMello et al. Sep 1989 A
4884579 Engelson Dec 1989 A
4927642 Kunz May 1990 A
4932938 Goldberg et al. Jun 1990 A
4936835 Haaga Jun 1990 A
5041090 Scheglov et al. Aug 1991 A
5049140 Brenner et al. Sep 1991 A
5080655 Haaga Jan 1992 A
5084063 Korthoff Jan 1992 A
5092848 deCiutiis Mar 1992 A
5108407 Geremia et al. Apr 1992 A
5122136 Guglielmi et al. Jun 1992 A
5192301 Kamiya et al. Mar 1993 A
5207648 Gross May 1993 A
5215530 Hogan Jun 1993 A
5221267 Folden Jun 1993 A
5258042 Mehta Nov 1993 A
5263964 Purdy Nov 1993 A
5334217 Das Aug 1994 A
5360414 Yarger Nov 1994 A
5360418 Weilbacher et al. Nov 1994 A
5375612 Cottenceau et al. Dec 1994 A
5395353 Scribner Mar 1995 A
5405339 Kohnen et al. Apr 1995 A
5413791 Rhee et al. May 1995 A
5443454 Tanabe et al. Aug 1995 A
5507731 Hernandez et al. Apr 1996 A
5522883 Slater et al. Jun 1996 A
5569221 Houser et al. Oct 1996 A
5570585 Vaynberg Nov 1996 A
5580568 Greff et al. Dec 1996 A
5603698 Roberts et al. Feb 1997 A
5645558 Horton Jul 1997 A
5667767 Greff et al. Sep 1997 A
5683370 Luther et al. Nov 1997 A
5690644 Yurek et al. Nov 1997 A
5695480 Evans et al. Dec 1997 A
5702361 Evans et al. Dec 1997 A
5733267 Del Toro Mar 1998 A
5749894 Engelson May 1998 A
5766219 Horton Jun 1998 A
5776097 Massoud Jul 1998 A
5791036 Goodin et al. Aug 1998 A
5795331 Cragg et al. Aug 1998 A
5830178 Jones et al. Nov 1998 A
5833644 Zando-Azizi et al. Nov 1998 A
5895378 Nita Apr 1999 A
5895385 Guglielmi et al. Apr 1999 A
5895410 Forber et al. Apr 1999 A
5902310 Foerster et al. May 1999 A
5921954 Mohr, Jr. et al. Jul 1999 A
5928226 Guglielmi et al. Jul 1999 A
5928260 Chin et al. Jul 1999 A
5928266 Kontos Jul 1999 A
5951599 McCrory Sep 1999 A
5957912 Heitzmann Sep 1999 A
5984964 Roberts et al. Nov 1999 A
6010498 Guglielmi Jan 2000 A
6015424 Rosenbluth et al. Jan 2000 A
6022369 Jacobsen et al. Feb 2000 A
6051607 Greff Apr 2000 A
6059815 Lee et al. May 2000 A
6063318 Houser et al. May 2000 A
6077260 Wheelock et al. Jun 2000 A
6090125 Horton Jul 2000 A
6093199 Brown et al. Jul 2000 A
6102917 Maitland et al. Aug 2000 A
6102932 Kurz Aug 2000 A
6136015 Kurz et al. Oct 2000 A
6146373 Cragg et al. Nov 2000 A
6152144 Lesh et al. Nov 2000 A
6152913 Feith et al. Nov 2000 A
6159165 Ferrera et al. Dec 2000 A
6165178 Bashiri et al. Dec 2000 A
6165193 Greene, Jr. et al. Dec 2000 A
6168570 Ferrera Jan 2001 B1
6168615 Ken et al. Jan 2001 B1
6171326 Ferrera et al. Jan 2001 B1
6179860 Fulton, III et al. Jan 2001 B1
6203779 Ricci et al. Mar 2001 B1
6224610 Ferrera May 2001 B1
6228055 Foerster et al. May 2001 B1
6238403 Greene, Jr. et al. May 2001 B1
6241691 Ferrera et al. Jun 2001 B1
6245053 Benjamin Jun 2001 B1
6258079 Burbank et al. Jul 2001 B1
6270477 Bagaosian et al. Aug 2001 B1
6277126 Barry et al. Aug 2001 B1
6293960 Ken Sep 2001 B1
6296622 Kurz et al. Oct 2001 B1
6299619 Greene, Jr. et al. Oct 2001 B1
6306124 Jones et al. Oct 2001 B1
6306153 Kurz et al. Oct 2001 B1
6319267 Kurz Nov 2001 B1
6322586 Monroe et al. Nov 2001 B1
6346091 Jacobsen et al. Feb 2002 B1
6361528 Wilson et al. Mar 2002 B1
6368301 Hamilton et al. Apr 2002 B1
6375774 Lunn et al. Apr 2002 B1
6409721 Wheelock et al. Jun 2002 B1
6463317 Kucharczyk et al. Oct 2002 B1
6475169 Ferrera Nov 2002 B2
6478773 Gandhi et al. Nov 2002 B1
6494884 Gifford, III et al. Dec 2002 B2
6497671 Ferrera et al. Dec 2002 B2
6500190 Greene, Jr. et al. Dec 2002 B2
6511468 Cragg et al. Jan 2003 B1
6524274 Rosenthal et al. Feb 2003 B1
6551340 Konya et al. Apr 2003 B1
6558367 Cragg et al. May 2003 B1
6585748 Jeffree Jul 2003 B1
6589236 Wheelock et al. Jul 2003 B2
6596217 Davis-Lemessy et al. Jul 2003 B1
6602261 Greene, Jr. et al. Aug 2003 B2
6607538 Ferrera et al. Aug 2003 B1
6616617 Ferrera et al. Sep 2003 B1
6638291 Ferrera et al. Oct 2003 B1
6656214 Fogarty et al. Dec 2003 B1
6663607 Slaikeu et al. Dec 2003 B2
6673058 Snow Jan 2004 B2
6679903 Kurz Jan 2004 B2
6689141 Ferrera et al. Feb 2004 B2
6716223 Leopold et al. Apr 2004 B2
6723108 Jones et al. Apr 2004 B1
6730095 Olson, Jr. et al. May 2004 B2
6743236 Barry et al. Jun 2004 B2
6743251 Eder Jun 2004 B1
6790221 Monroe et al. Sep 2004 B2
6835185 Ramzipoor et al. Dec 2004 B2
6852261 Benjamin Feb 2005 B2
6905503 Gifford, III et al. Jun 2005 B2
6966892 Gandhi et al. Nov 2005 B2
6997937 Jacobsen et al. Feb 2006 B2
7014645 Greene, Jr. et al. Mar 2006 B2
7066904 Rosenthal et al. Jun 2006 B2
7070608 Kurz et al. Jul 2006 B2
7147618 Kurz Dec 2006 B2
7179276 Barry et al. Feb 2007 B2
7182774 Barry et al. Feb 2007 B2
7198613 Gandhi et al. Apr 2007 B2
7229454 Tran et al. Jun 2007 B2
7255707 Ramzipoor et al. Aug 2007 B2
7316701 Ferrera et al. Jan 2008 B2
7326225 Ferrera et al. Feb 2008 B2
7338511 Mirigian et al. Mar 2008 B2
7507230 Li et al. Mar 2009 B2
7591822 Olson, Jr. et al. Sep 2009 B2
20010001117 Chow May 2001 A1
20020007194 Plowiecki Jan 2002 A1
20020095174 Tsugita et al. Jul 2002 A1
20020111646 Gifford, III et al. Aug 2002 A1
20020165582 Porter Nov 2002 A1
20020198440 Snow Dec 2002 A1
20030040733 Cragg et al. Feb 2003 A1
20030139761 Jergensen et al. Jul 2003 A1
20030176857 Lee Sep 2003 A1
20030229277 Kolberg et al. Dec 2003 A1
20040044330 Li et al. Mar 2004 A1
20040049153 Holman et al. Mar 2004 A1
20040133222 Tran et al. Jul 2004 A1
20040138625 Flodin Jul 2004 A1
20040186464 Mamayek et al. Sep 2004 A1
20040225279 Raymond Nov 2004 A1
20040236364 Jones Nov 2004 A1
20040254528 Adams et al. Dec 2004 A1
20040260333 Dubrul et al. Dec 2004 A1
20050038470 van der Burg et al. Feb 2005 A1
20050043703 Nordgren Feb 2005 A1
20050159773 Broome et al. Jul 2005 A1
20050228360 Kelley Oct 2005 A1
20050245962 Adams et al. Nov 2005 A1
20050261725 Crawford et al. Nov 2005 A1
20050273152 Campbell Dec 2005 A1
20060106421 Teoh May 2006 A1
20060116636 Murphy et al. Jun 2006 A1
20060142702 Sievers et al. Jun 2006 A1
20060271085 Siess et al. Nov 2006 A1
20070178131 Yamada et al. Aug 2007 A1
20070213764 Tran et al. Sep 2007 A1
20080045922 Cragg et al. Feb 2008 A1
20080103476 Schulte May 2008 A1
20080108974 Yee Roth May 2008 A1
20080228173 Plowiecki Sep 2008 A1
20080294104 Mawad Nov 2008 A1
20090044811 Welchel et al. Feb 2009 A1
20090048615 McIntosh Feb 2009 A1
20091026485 Nash et al. Oct 2009
20100049165 Sutherland Feb 2010 A1
20120157854 Kurrus Jun 2012 A1
20140135737 Sutherland et al. May 2014 A1
Foreign Referenced Citations (45)
Number Date Country
102186526 Sep 2011 CN
1875646 Jul 1963 DE
2541919 Mar 1977 DE
8614013 Aug 1986 DE
3632573 Apr 1988 DE
08619671 Apr 1989 DE
19610333 Sep 1997 DE
29908453 Sep 1999 DE
20319306 Jun 2005 DE
0375775 Jul 1990 EP
0446804 Sep 1991 EP
0645161 Feb 2002 EP
1207791 Oct 2004 EP
2896421 Jul 2007 FR
03168156 Jul 1991 JP
447416 Apr 1992 JP
H07503808 Apr 1995 JP
7508909 Oct 1995 JP
11-513606 Nov 1999 JP
2001520085 Oct 2001 JP
2006509578 Mar 2006 JP
2006088079 Apr 2006 JP
1008178 Aug 1999 NL
889009 Dec 1981 SU
9112847 Sep 1991 WO
9316505 Aug 1993 WO
9317745 Sep 1993 WO
9410936 May 1994 WO
9715257 May 1997 WO
9715257 May 1997 WO
9727893 Aug 1997 WO
9920326 Apr 1999 WO
9922651 May 1999 WO
9939649 Aug 1999 WO
9942038 Aug 1999 WO
9948548 Sep 1999 WO
0001308 Jan 2000 WO
0115608 Mar 2001 WO
02096301 Dec 2002 WO
03013639 Feb 2003 WO
03037419 May 2003 WO
2004002340 Jan 2004 WO
2004054452 Jul 2004 WO
2004062511 Jul 2004 WO
2007039678 Apr 2007 WO
Non-Patent Literature Citations (21)
Entry
European Search Report dated Sep. 23, 2013 from corresponding European Application No. 13169745.0. (5 pgs.).
Notice of Final Rejection, and translation thereof, from counterpart Korean Patent Application No. 10-2013-69432, dated Feb. 26, 2015, 7 pp.
Notification of the First Office Action, and translation thereof, from counterpart Chinese Patent Application No. 201310240253.1, dated Dec. 9, 2014, 17 pp.
Notice of Preliminary Rejection, and translation thereof, from counterpart Korean Patent Application No. 10201369432, dated Aug. 29, 2014, 10 pp.
Notice of Reasons for Rejection, and translation thereof, from counterpart Japanese Patent Application No. 2013119620, dated Apr. 30, 2014, 16 pp.
Office Action from counterpart Canadian Patent Application No. 2815040, dated Jun. 4, 2014, 3 pp.
Office Action from counterpart Canadian Application No. 2,815,040, dated May 19, 2015, 3 pp.
Balt Extrusion, Sonic Flow-Directed Braided Microcatheter, www.balt.fr, 2008, 4 pp.
Byrne, “Review Article: Endovascular Treatments for Intracranial Aneurysms,” The British Journal of Radiology, vol. 69, No. 826, Oct. 1996, pp. 891-899.
Jeffree et al., “The Porous, Guidewire-Directed, Detachable Aneurysm Liner: A New Concept in the Endovascular Treatment of Intracranial Aneurysms,” American Journal of Neuroradiology, vol. 20, May 1999, pp. 774-779.
Kassell et al., “Size of Intracranial Aneurysms,” Neurosurgery, vol. 12, No. 3, Mar. 1983, pp. 291-297.
Schievink, “Intracranial Aneurysms,” The New England Journal of Medicine, vol. 336, No. 1, Jan. 2, 1997, pp. 28-40.
Szikora et al., “Combined Use of Stents and Coils to Treat Experimental Wide-Necked Carotid Aneurysms: Preliminary Results,” American Journal of Neuroradiology, vol. 15, Jun. 1994, pp. 1091-1102.
Szikora et al., “Endovascular Treatment of Experimental Aneurysms with Liquid Polymer: The Protective Potential of Stents,” Neurosurgery, vol. 38, No. 2, Feb. 1996, pp. 339-347.
Turjman et al., “Combined Stent Implantation and Endosaccular Coil Placement for Treatment of Experimental Wide-Necked Aneurysms: A Feasibility Study in Swine,” American Journal of Neuroradiology, vol. 15, Jun. 1994, pp. 1087-1090.
Yoshimoto et al., “Cerebral Aneurysms Unrelated to Arterial Bifurcations,” Acta Neurochirurgica, The European Journal of Neurosurgery, vol. 138, No. 8, 1996, pp. 958-964.
Notice of Last Preliminary Rejection, and translation thereof, from counterpart Korean Patent Application No. 10-2013-0069432, dated Jun. 26, 2015, 9 pp.
Second Office Action, and translation thereof, from counterpart Chinese Patent Application No. 201310240253.1, dated Sep. 1, 2015, 14 pp.
Second Final Rejection, and translation thereof, from counterpart Korean Application No. 10-2013-0069432, dated Aug. 5, 2016, 5 pp.
Notice of Preliminary Rejection, and translation thereof, from counterpart Korean Application No. 10-2013-0069432, dated Dec. 30, 2015, 9 pp.
Office Action, and English translation thereof, from counterpart Indian Application No. 1409/DEL/2013, dated Aug. 17, 2018, 6 pp.
Related Publications (1)
Number Date Country
20130338643 A1 Dec 2013 US